共 50 条
- [1] A PHASE 1A/B STUDY OF IK-175, AN ORAL AHR INHIBITOR, ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH LOCALLY DVANCED OR METASTATIC SOLID TUMORS AND UROTHELIAL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A425 - A425McKean, MeredithLuke, JasonLakhani, NehalBashir, BabarAggen, DavidTan, AlanKacena, KatherineWang, LeiTimothy, MarissaSantillana, Sergio
- [2] INITIAL RESULTS FROM A PHASE 1A/B STUDY OF IK175, AN ORAL AHR INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS AND UROTHELIAL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A692 - A692Aggen, DavidMcKean, MeredithLakhani, NehalBashir, BabarHoffman-Censits, JeanAlhalabi, OmarGuancial, ElizabethBowman, IsaacTan, AlanLingaraj, TruptiTimothy, MarissaOrtiz-Otero, NerymarBartolini, WilminKacena, KatherineMalek, KarimSantillana, SergioLuke, Jason
- [3] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid TumorsCLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892Mettu, Niharika B.Ulahannan, Susanna, VBendell, Johanna C.Garrido-Laguna, IgnacioStrickler, John H.Moore, Kathleen N.Stagg, RobertKapoun, Ann M.Faoro, LeonardoSharma, Sunil
- [4] A PHASE 1B OPEN-LABEL, SINGLE-ARM DOSE EXPANSION STUDY OF IK-175, AN ORAL AHR INHIBITOR, IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH PRIMARY PD-1 INHIBITOR RESISTANT ADVANCED HEAD AND NECK CANCERJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A710 - A710Lingaraj, TruptiTimothy, MarissaOrtiz-Otero, NerymarBartolini, WilminKacena, KatherineMalek, KarimSantillana, Sergio
- [5] IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Aggen, David H.McKean, MeredithHoffman-Censits, Jean H.Lakhani, Nehal J.Alhalabi, OmarGuancial, Elizabeth A.Bashir, BabarBowman, I. AlexTan, AlanLingaraj, TruptiKim, KatherineTimothy, MarissaOrtiz-Otero, NerymarBartolini, WilminKacena, KatherineSantillana, SergioLuke, Jason J.
- [6] ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinomaCANCER RESEARCH, 2019, 79 (13)Grivas, PetrosTeo, Min YuenVogelzang, NicholasAlva, AjjaiZakharia, YousefAdra, NabilDrakaki, AlexandraHussain, ArifMorales-Barrera, RafaelNecchi, AndreaRodriguez-Vida, AlejoFeyerabend, SusanGupta, SumatiJosephs, Debra H.Loriot, YohannSrinivas, SandyWride, KentonThomas, DaleenDusek, RachelSimmons, Andrew D.Nepert, DaleChowdhury, Simon
- [7] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)Grivas, PetrosVogelzang, Nicholas J.Alva, Ajjai ShivaramFeyerabend, SusanLoriot, YohannNecchi, AndreaGupta, SumatiJosephs, Debra HannahRodriguez-Vida, AlejoSrinivas, SandyZakharia, YousefWride, KentonThomas, DaleenDusek, RachelSimmons, AndrewNepert, Dale L.Chowdhury, Simon
- [8] ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinomaONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 324Feyerabend, S.Boegemann, M.Goebell, P. J.Stoeckle, M.Nepert, D.Wride, K.Thomas, D.Loehr, A.Simmons, A.Grivas, P.Chowdhury, S.
- [9] ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Grivas, PetrosNepert, Dale L.Wride, KentonThomas, DaleenLoehr, AndreaSimmons, Andrew
- [10] ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinomaANNALS OF ONCOLOGY, 2018, 29Chowdhury, S.Feyerabend, S.Loriot, Y.Necchi, A.Gupta, S.Josephs, D. H.Rodriguez-Vida, A.Srinivas, S.Zakharia, Y.Nepert, D.Wride, K.Thomas, D.Loehr, A.Simmons, A. D.Grivas, P.